Tag Archives: ITG

Top 10 Medical Stocks To Own Right Now

Contrary to popular belief, hemp and marijuana aren’t the same thing. The difference between hemp and marijuana is primarily the amount of tetrahydrocannabinol (or THC), or is the primary psychoactive chemical in marijuana. Hemp contains less than 0.5% THC, while marijuana consists of anywhere from 6 % to 20% (and sometimes more) THC.

Granted, it’s not always a fully-appreciated distinction. Even though the federal government accurately recognizes that hemp and marijuana are only variants of the same species, Cannabis sativa, the DEAdoesn’t necessarily enforce its drug laws as such. For legitimate medical purposes, the government is perfectly willing to leave the matter alone.

The good news is, governments – federal as well as state – are finally starting to figure out the distinct differences between marijuana and hemp, and that bodes well for a young and hungry startup called Lexaria Bioscience Corp (OTCMKTS:LXRP).

Top 10 Medical Stocks To Own Right Now: SPDR Wells Fargo Preferred Stock ETF (PSK)

Advisors’ Opinion:

  • [By Todd Shriber, ETF Professor]

    DWFI holds five other SSgA fixed income ETFs, including the SPDR Wells Fargo Preferred Stock ETF (NYSE: PSK). PSK is DWFI's largest holding at a weight of 25.2 percent. DWFI's second-largest holding is an allocation of almost 25 percent to the SPDR Nuveen Barclays Municipal Bond ETF (NYSE: TFI).

Top 10 Medical Stocks To Own Right Now: Investment Technology Group, Inc.(ITG)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Investment Technology Group Inc. (NYSE: ITG) was downgraded to Market Perform from outperform by KeefeBruyette & Woods.

    Liquidity Services Inc. (NASDAQ: LQDT) was raised to Buy from Underperform, and the price target was raised up to $45 from $28.50, at Merrill Lynch.

Top 10 Medical Stocks To Own Right Now: Manitex International Inc.(MNTX)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Thursday, industrial shares fell by 0.08 percent. Meanwhile, top losers in the sector included Accenture Plc (NYSE: ACN), down 4 percent, and Manitex International Inc (NASDAQ: MNTX), down 4 percent.

Top 10 Medical Stocks To Own Right Now: Coherent, Inc.(COHR)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Rofin-Sinar Technologies (NASDAQ: RSTI) got a boost, shooting up 37 percent to $31.50 as Coherent, Inc. (NASDAQ: COHR) announced its plans to buy Rofin-Sinar Technologies Inc in a deal valued at around $942 million.

Top 10 Medical Stocks To Own Right Now: 8×8 Inc(EGHT)

Advisors’ Opinion:

  • [By Anders Bylund]

    Shares of 8×8 (NASDAQ:EGHT) rose 26.6% in 2016, according to data from S&P Global Market Intelligence.

    So what

    The provider of internet-based voice and communications services put together a remarkable financial record last year. 8X8 beat Wall Street’s earnings and sales estimates handily in each one of the year’s quarterly reports,citing strong organic revenue growth among larger customers along the way. Large-scale corporate customers accounted for 53% of the company’s total sales in the recently reported second quarter, and these big clients are also showing strong loyalty to the 8×8 brand by renewing their service contracts.

  • [By Peter Graham]

    A long term performance chart shows small cap magicJack VocalTec Ltd underperforming versus VOIP related peers Vonage Holdings Corp (NYSE: VG)and 8×8, Inc (NASDAQ: EGHT) which have been volatile, but have been heading higher:

  • [By Peter Graham]

    A long term performance chart shows small cap magicJack VocalTec Ltd hitting lower highs and lowerlows for some years now but also leveling off while VOIP related peers Vonage Holdings Corp (NYSE: VG)and 8×8, Inc (NASDAQ: EGHT) have been volatile, but also largely heading higher:

  • [By Lisa Levin]

    Telecommunications services shares climbed 0.56 percent in trading on Thursday. Meanwhile, top gainers in the sector included Frontier Communications Corp (NASDAQ: FTR), and 8×8, Inc. (NASDAQ: EGHT).

Top 10 Medical Stocks To Own Right Now: Ashford Hospitality Trust Inc(AHT)

Advisors’ Opinion:

  • [By Lisa Levin] Related AHT 25 Biggest Mid-Day Gainers For Friday Mid-Day Market Update: Hortonworks Drops Following Weak Results; Freshpet Shares Spike Higher Ashford Hospitality Trust's (AHT) CEO Montgomery Bennet on Q2 2016 Results – Earnings Call Transcript (Seeking Alpha)
    Related NEWS Mid-Morning Market Update: Markets Open Higher; Micron To Lower Jobs Mid-Morning Market Update: Markets Open Lower; Broadcom Profit Beats Expectations NewStar Financial's (NEWS) CEO Tim Conway on Q2 2016 Results – Earnings Call Transcript (Seeking Alpha)

     

Top 10 Medical Stocks To Own Right Now: RELM Wireless Corporation(RWC)

Advisors’ Opinion:

  • [By Jim Robertson]

    Today, our Under the Radar Moversnewsletter suggested shorting small cap wireless communications manufacturer RELM Wireless Corporation (NYSEMKT: RWC):

Top 10 Medical Stocks To Own Right Now: Zimmer Biomet Holdings, Inc.(ZBH)

Advisors’ Opinion:

  • [By WWW.GURUFOCUS.COM]

    For the details of Focused Investors LLC’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=Focused+Investors+LLC

    These are the top 5 holdings of Focused Investors LLCZimmer Biomet Holdings Inc (ZBH) – 1,433,300 shares, 6.32% of the total portfolio. Shares added by 23.22%CVS Health Corp (CVS) – 2,120,700 shares, 6.01% of the total portfolio. Shares added by 19.73%Johnson & Johnson (JNJ) – 1,285,900 shares, 5.78% of the total portfolio. Shares reduced by 0.67%American Express Co (AXP) – 1,990,300 shares, 5.68% of the total portfolio. Shares reduced by 0.33%Anthem Inc (ANTM) – 944,800 shares, 5.64% of the total portfolio. Sh

  • [By Keith Speights]

    The three top dividend stocks in the dentistry industry are Patterson Companies (NASDAQ:PDCO), Zimmer Biomet Holdings (NYSE:ZBH), and Danaher (NYSE:DHR). But two of these, Zimmer Biomet and Danaher, pay out only small dividends.

Top 10 Medical Stocks To Own Right Now: Unilever NV(UN)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Tuesday, industrial shares fell by 0.04 percent. Meanwhile, top losers in the sector included Unilever N.V. (ADR) (NYSE: UN), down 8 percent, and Magal Security Systems Ltd. (USA) (NASDAQ: MAGS), down 6 percent.

  • [By Teresa Rivas]

    Earlier this year, Unilever (UN) recently declined Kraft Heinz (KHC) merger bid. That means that if the company still wants to do a deal, Mondelez International (MDLZ) and PepsiCo (PEP) are the next logical partners, writes Susquehannas Pablo Zuanic.

    Getty Images

    Zuanic upgraded Pepsi from Neutral to Positive today and raised his price target from $118 to $132. He writes that a Pepsi deal would have more strategic merits, hence his upgrade (as he emphasizes that not much has changed in terms of fundamentals for the firm).

    More detail from his note:

    With investors apparently seeing MDLZ as the next likely KHC target, and Coca-Cola (KO) the next Anheuser-Busch (BUD) target, PEP shares have lost visibility and now trade at a 25% discount to KO on apples-to-apples comps. We see value here, on franchise strength, efforts to align the F&B portfolio with consumer health trends, and the growing optionality value of a joint KHC/BUD bid for PEP. We argue that, together, the Kendall Jenner commercial, the Aspartame to-be-or-not-to-be zigzagging, the new, new, new alt low-cal cola (Pepsi Zero sugar), the ongoing underperformance in U.S. CSDs (25% only of the company), the lack of scale in non-CSD NARTDs vs. KO (other than Gatorade), and now talk of PEP buying Brazilian dairy company Vigor S.A. (a JBS subsidiary that would better fit KHC or ULVR), all paint a picture of a company still struggling to set a new direction (with all due respect). In this regard, we think PEP may be more vulnerable than MDLZ to a KHC bid (jointly done with BUD). We also see greater strategic fit for KHC with PEP Food/Snacks (than with MDLZ), and argue that PEP Beverages fits BUD better than KO, as the PEP bottling operations in key regions (including NA) remain in the hands of PEP (KO, on the other hand will be fully refranchised by end of 2017). So we are upgrading PEP to Positive with a $132 price target by December 17. Yes, the Unilever rebuff

Top 10 Medical Stocks To Own Right Now: Bank Of Montreal(BMO)

Advisors’ Opinion:

  • [By Mitchell Clark]

     Banks can produce solid earnings growth in the early stages of a rising interest rate environment. This Canadian bank is not expensively priced on the stock market. It currently has an over four percent dividend yield.

    The Canadian banking market is small, but it’s protected from foreign ownership and most of the names in this industry have great long-term track records on the stock market.

candlestick chart

5 Tax Bill Conference Report Sections for Agents to Watch

9 Details That Could Be Signs of Life Insurance Fraud

Americo Introduces a Single-Premium Immediate LTCI Policy

A long-running lawsuit between the Trump administration, House Republicans and Democratic attorneys general over billions of dollars of Affordable Care Act public exchange plan subsidies has been settled, according to an agreement filed in federal court Friday.

The settlement agreement, details of which weren’t available in the filings but described as “conditional,” could pave the way for eventual payment of the cost-sharing reduction payments, or CSRs. The CSRs had been paid to health insurers as a way to subsidize some lower-income patients’ insurance co-payments and deductibles, allowing them easier access to health care.

(Related: ACA Mandate Clobbers ACA Subsidy: CBO)

The Trump administration had stopped making the payments, throwing the Affordable Care Act’s markets into chaos and causing premiums to rise, and state Democratic attorneys general continued the legal effort to try and preserve the subsidies.

candlestick chart: Investment Technology Group, Inc.(ITG)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Investment Technology Group Inc. (NYSE: ITG) was downgraded to Market Perform from outperform by KeefeBruyette & Woods.

    Liquidity Services Inc. (NASDAQ: LQDT) was raised to Buy from Underperform, and the price target was raised up to $45 from $28.50, at Merrill Lynch.

candlestick chart: Nu Skin Enterprises Inc.(NUS)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Citigroup’s Beth Kite calls Nu Skin Enterprises’ (NUS) earnings and guidance “awfully disappointing.” She explains why:

    “Frustrating” Describes 4Q15 & 2016 Guidance:Nu Skin (i) reported 4Q15 EPS of $0.62, 11 cents below consensus and us, and (ii) lowered 2016 EPS guidance, from $3.25-$3.40 to $2.40-$2.60.Nu Skin had three LTO’s in 4Q152 succeeded and 1 failed. The failure had far less to do with the product than with the sales strategy…

    Is Guidance Too Conservative or Is It Really This Bad? We get that Me failed to sell well in South Korea with the 12-month cartridge commitment. But given the strength in reps globally, the strength of Youth from its two LTOs in 2H15, and good results from Me when sold in Japan without the 12-month commitment, we wonder if guidance is aggressive to the downside. Indeed, the word “conservative” was said a lot by mgmt on the brief earnings call when describing guidance revisions.

    Maintaining Buy: While we now have less confidence in mgmt, from an external perspective, to forecast its results accurately, and from an internal perspective, to course correct quicklyi.e., why didn’t they drop the 12-month plan for Me in South Korea when it so obviously wasn’t workingwe are still confident in Youth & Me. The rep growth in South Asia/Pacific from Youth in 3Q led to better 4Q sales than we’d expected, Youth’s Americas LTO in 4Q drove lc sales up 26% YoY, and Me not only sold through in Japan in 4Q but also drove reps higher. We imagine that investors may have little patience or confidence in Nu Skin for a while, understandably. But the bar seems set fairly low now, so we are cautiously optimistic that Nu Skin can dig itself out of this hole as we go through 2016 and Me & Youth roll out more fully.

    Shares of Nu Skin have tumbled 13% to $27.31 at 2:11 p.m. today.

  • [By Roberto Pedone]

    Nu Skin Enterprises (NUS) is a direct selling company, which develops and distributes personal care products and nutritional supplements that are sold under the Nu Skin and Pharmanex brands. This stock closed up 5.4% at $92.96 in Monday’s trading session.

    Monday’s Volume: 2 million

    Three-Month Average Volume: 900,802

    Volume % Change: 85%

    From a technical perspective, NUS ripped higher here right above some near-term support at $85 with heavy upside volume. This move pushed shares of NUS into breakout and new 52-week-high territory, since the stock took out some near-term overhead resistance levels at $88.20 to $89.69. This move also pushed shares of NUS above the upper-end of its recent range that saw the stock trend between $82 to just above $89.

    Traders should now look for long-biased trades in NUS as long as it’s trending above support at $85 and then once it sustains a move or close above Monday’s high of $93.33 with volume that this near or above 900,802 shares. If we get that move soon, then NUS will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $100 to $105.

  • [By Scott Rubin]

    Stock gainers included Mercadolibre Inc (NASDAQ: MELI), up almost 14 percent, and Nu Skin Enterprises, Inc. (NYSE: NUS), which added 12 percent. The positive gains in both stocks were due to strong earnings reports. Shares of Liberty Interactive Group (NASDAQ: QVCA) plunged almost 22 percent on Friday due to disappointing sales growth in its fiscal second quarter. Pharmaceutical giant Bristol-Myers Squibb Co (NYSE: BMY) lost 16 percent after a disappointing study involving its Opdivo drug.

  • [By Craig Jones]

    Nu Skin Enterprises, Inc. (NYSE: NUS) is trading sharply higher on Friday, but options traders are buying puts in the name, said Jon Najarian. Traders were buying the June 50 puts and they paid around 6 percent for them, so they don't see much upside in Nu Skin Enterprises, explained Najarian. He followed the trade and he is planning to hold the position for a month.

candlestick chart: Vanguard Extended Duration Treasury ETF (EDV)

Advisors’ Opinion:

  • [By Todd Shriber, ETF Professor]

    The 11 ETF fee cuts unveiled by Vanguard include a significant portion of the issuer's fixed income lineup. All of the following saw annual fees reduced to 0.07 percent from 0.1 percent:

    Vanguard Extended Duration Treasury ETF (NYSE: EDV). Vanguard Intermediate-Term Bond ETF (NYSE: BIV). Vanguard Intmdte Tm Govt Bd ETF (NASDAQ: VGIT). Vanguard Long Term Corporate Bond ETF (NASDAQ: VCLT). Vanguard Lg Term Govt Bd ETF (NASDAQ: VGLT). Vanguard Mortgage Bkd Sects ETF (NASDAQ: VMBS).

    and the Vanguard Short Term Corporate Bond ETF (NASDAQ: VCSH).

candlestick chart: VALE S.A.(VALE)

Advisors’ Opinion:

  • [By Craig Jones]

    On CNBC's Fast Money Halftime Report, Jon Najarian spoke about unusually high put options activity in Arconic Inc (NYSE: ARNC) and Vale SA (ADR) (NYSE: VALE).

  • [By Ben Levisohn]

    Mosaic (MOS) tumbled to the bottom of the S&P 500 today after announcing that it would buy Vale’s (VALE) fertilizer unit.

    Getty Images

    Mosaicdropped 1.1% to $27.77 today, while the S&P 500 advanced 0.2% to 2,262.53.

candlestick chart: Intercontinental Exchange Inc.(ICE)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Altria (MO) , Intercontinental Exchange (ICE) and Micron Technology (MU) .

    Cramer was bearish on NVIDIA (NVDA) and Reynolds American (RAI) .

candlestick chart: Vanda Pharmaceuticals Inc.(VNDA)

Advisors’ Opinion:

  • [By Roberto Pedone]

    Another biotechnology player that looks poised to trigger a big breakout trade is Vanda Pharmaceuticals (VNDA), which is focused on the development and commercialization of clinical-stage drug candidates for central nervous system disorders. This stock has been on fire so far in 2013, with shares up a whopping 258%.

    If you take a look at the chart for Vanda Pharmaceuticals, you’ll notice that this stock has recently broke out above some near-term overhead resistance levels at $12.34 to $12.66 a share with solid upside volume. So far, this breakout has held and now shares of VNDA are quickly moving within range of triggering an even bigger breakout trade.

    Traders should now look for long-biased trades in VNDA if it manages to break out above its 52-week high at $13.30 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action 908,467 shares. If that breakout hits soon, then VNDA will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $15 to $17 a share.

    Traders can look to buy VNDA off any weakness to anticipate that breakout and simply use a stop that sits right below some near-term support at $12 a share. One could also buy VNDA off strength once it takes out $13.30 a share with volume and then simply use a stop that sits a comfortable percentage from your entry point.

stock market trading software

Though 2016 may be coming to a close, it’s not too late to do some last-minute tax planning. Here are a few tax breaks that could shield more of your money from the Internal Revenue Service this year.

1. Retirement plan contributions

Saving independently for retirement can help ensure that you don’t run out of money during your senior years. But there are also tax benefits to saving, so if you’ve yet to max out your retirement plan contributions for 2016, now’s the time to ramp up. The money you put into a 401(k) or traditional IRA goes in on a pre-tax basis, which means every dollar you put in this year is a dollar you won’t pay taxes on. If you’re under 50, you can contribute up to $18,000 in 2016 to a 401(k) and $5,500 to an IRA. If you’re 50 or older, you’re allowed to put up to $24,000 into a 401(k) and $6,500 into an IRA. But don’t wait to increase that 401(k) contribution — it might take your company a couple of weeks to process your payroll adjustment, so be sure to put in that request right away if you want it to count for this year.

stock market trading software: Cara Therapeutics, Inc.(CARA)

Advisors’ Opinion:

  • [By Javier Hasse]

    On the other hand, Cara Therapeutics Inc (NASDAQ: CARA) was up almost 1.9 percent in what also looked like a correction of the 1.6 percent gain registered over the regular trading session.

  • [By WWW.THESTREET.COM]

    In the Lightning Round, Cramer was bullish on Cara Therapeutics (CARA) , Verizon (VZ) , Radius Health (RDUS) and Six Flags (SIX) .

    Cramer was bearish on Hertz Global Holdings (HTZ) , General Motors (GM) , Pandora Media (P) , Cedar Fair (FUN) , Quotient Technology (QUOT) and Rite Aid (RAD) .

stock market trading software: Cyclacel Pharmaceuticals Inc.(CYCC)

Advisors’ Opinion:

  • [By Alex McGuire]

    As a service to our readers, the following list provides the 10 top pharmaceutical stocks to watch this month (May 2017), including the biggest gainers from April…

    Pharmaceutical Stock Current Share Price April 2017 Gain
    Cleveland BioLabs Inc. (Nasdaq: CBLI) $3.62 +120.6%
    Nexvet Biopharma Plc. (Nasdaq: NVET) $6.61 +69.7%
    Motif Bio Plc. (Nasdaq ADR: MTFB) $10.10 +68.2%
    Axovant Sciences Ltd. (NYSE: AXON) $24.43 +62.3%
    Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC) $5.49 +46.7%
    Conatus Pharmaceuticals Inc. (Nasdaq: CNAT) $8.67 +44.9%
    Akebia Therapeutics Inc. (Nasdaq: AKBA) $13.07 +43.3%
    Akorn Inc. (Nasdaq: AKRX) $33.28 +38.9%
    Rockwell Medical Inc. (Nasdaq: RMTI) $8.78 +37.4%
    Akari Therapeutics Plc. (Nasdaq ADR: AKTX) $15.02 +35.4%

    The best-performing pharma stock of the month – Cleveland BioLabs Inc. – surged 120.6% to $3.53 a share by April 28. That crushed both the Nasdaq Biotech Index’s 1.5% gain and the Dow Jones’ 1.3% rise over the same period.

  • [By Alex McGuire]

    These are the 10 best penny stocks that have seen the biggest returns over the last week (March 7 – March 14)…

    Penny StockCurrent PriceWeekly Gain (March 7 – March 14)Ocera Therapeutics Inc. (Nasdaq: OCRX)$1.47+147.1%Internap Corp. (Nasdaq: INAP)$3.28+41.4%Soligenix Inc. (Nasdaq: SNGX)$2.94+40%Navios Maritime Partners LP (NYSE: NMM)$2.63+37%QuickLogic Corp. (Nasdaq: QUIK)$2.14+30.5%Adamis Pharmaceuticals Corp. (Nasdaq: ADMP)$4.60+22.7EXCO Resources Inc. (NYSE: XCO)$0.65+20.5%Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC)$4.38+20.3%Hebron Technology Co. Ltd. (Nasdaq: HEBT)$3.99+19.1%Curis Inc. (Nasdaq: CRIS)$2.85+18.4%

    As a reminder, this is only a tracking metric of penny stocks trading on SEC-regulated exchanges like the Nasdaq and NYSE. Although these top penny stocks are safer than those trading on the pink sheets, we don’t recommend buying any of them without the proper amount of financial research.

stock market trading software: Tandem Diabetes Care, Inc.(TNDM)

Advisors’ Opinion:

  • [By Lisa Levin]

    Tandem Diabetes Care Inc (NASDAQ: TNDM) shares dropped 19 percent to $1.25. Tandem Diabetes Care priced its 18 million share offering at $1.25 per share.

  • [By Paul Ausick]

    Tandem Diabetes Care Inc. (NASDAQ: TNDM) dropped nearly 26% Thursday, to post a new 52-week low of $1.15 after closing at $1.55 on Wednesday. The stock’s 52-week high is $11.30. Volume was more than 20 times the daily average of around 290,000. The company announced an underwritten secondary offering of 18 million shares at $1.25 per share.

  • [By Lisa Levin]

    Shares of Tandem Diabetes Care Inc (NASDAQ: TNDM) were down 37 percent to $2.97 after the company reported a proposed offering of common stock and series A and B warrants.

  • [By Lisa Levin] Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha)
    Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha)
    Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period.
    Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share.
    Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement.
    Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share.
    Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76.
    QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share.
    Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering.
    Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and mileston

stock market trading software: Investment Technology Group, Inc.(ITG)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Investment Technology Group Inc. (NYSE: ITG) was downgraded to Market Perform from outperform by KeefeBruyette & Woods.

    Liquidity Services Inc. (NASDAQ: LQDT) was raised to Buy from Underperform, and the price target was raised up to $45 from $28.50, at Merrill Lynch.

stock market trading software: Vanguard FTSE Europe ETF (VGK)

Advisors’ Opinion:

  • [By Todd Shriber, ETF Professor]

    Still, there are instances of limited appetite for diversified Europe ETFs, particularly those with significant U.K. exposure. The Vanguard FTSE Europe ETF (NYSE: VGK) hasn't added (or lost) any capital since June 20. That ETF devotes 31.4 percent of its weight to U.K. stocks.

  • [By Todd Shriber, ETF Professor]

    Here is a dichotomy. Global small-caps are performing admirably. The WisdomTree Europe SmallCap Dividend Fund (NYSE: DFE) is an example of a Europe ETF that is defying some unfavorable trends. DFE is down 3.5 percent year-to-date. That sounds bad, but it is far better than what investors have been treated to with diversified, large-cap Europe ETFs. The Vanguard Europe ETF (NYSE: VGK) and the iShares Europe ETF (NYSE: IEV) are down an average of 5.3 percent this year.

  • [By Tom Aspray, Senior Editor, MoneyShow.com]

    The US stock market is still leading with the Spyder Trust (SPY) up 18.6%, while the European markets (VGK) are now up close to 10% for the year, as they have gotten a nice boost in the past three weeks.

  • [By Todd Shriber, ETF Professor]

    Perhaps the largest ETF dedicated to tracking French stocks should be getting more attention. In a year in which ETFs tracking the PIIGS economies are struggling, EWQ has been solid. The France ETF's 2.7 percent year-to-date gain is slightly ahead of the comparable Germany ETF and more than twice as good as the Vanguard FTSE Europe ETF (NYSE: VGK).

stock market trading software: Netease.com Inc.(NTES)

Advisors’ Opinion:

  • [By Joe Tenebruso]

    Shares ofNetEase (NASDAQ:NTES)popped 20.1% last month, according to data provided byS&P Global Market Intelligence, as the Chinese internet technology company’s strong fourth-quarter earnings report was applauded by investors.

  • [By Sreekanth Anasa]

    Shares of Hangzhou, China-based NetEase Inc (NASDAQ:NTES)popped 14% in the Feb 16th trading session after the company reported stellar Q4 and full-year 2016 earnings on Feb 15th after market close. The Chinese online gaming giant delivered an EPS of $4.30 on revenues of $1.74B beating EPS estimates by $0.86 and revenue estimates by $16oM. NetEase’s revenue grew by an impressive 53.1% YoY for Q4 and 67.7% for the full year 2016. On the back of these strong numbers, NTES stock closed at an all-time high of $298.73 in yesterday’s trading session. NTES stock might have gone up very high too soon. There could be a correction around the corner but still NTES stock is a great long-term proposition with much more upside left. Here’s why.